Abstract
Serotonergic psychedelics, substances exerting their effects primarily through the serotonin 2A receptor (5-HT2AR), continue to comprise a substantial portion of reported new psychoactive substances (NPS). The exact mechanisms of action of psychedelics still remain to be elucidated further, and certain pathways remain largely unexplored on a molecular level for this group of compounds. A systematic comparison of substances belonging to different subclasses, monitoring the receptor-proximal β-arrestin 2 recruitment, is lacking. Based on a previously reported in vitro bioassay employing functional complementation of a split nanoluciferase to monitor β-arrestin 2 recruitment to the 5-HT2AR, we here report on the setup of a stable HEK 293 T cell-based bioassay. Following verification of the performance of this new stable cell system as compared to a system based on transient transfection, the stable expression system was deemed suitable for the pharmacological characterization of psychedelic NPS. Subsequently, it was applied for the in vitro assessment of the structure–activity relationship of a set of 30 substances, representing different subclasses of phenylalkylamine psychedelics, among which 12 phenethylamine derivatives (2C-X), 7 phenylisopropylamines (DOx) and 11 N-benzylderivatives (25X-NB). The resulting potency and efficacy values provide insights into the structure–activity relationship of the tested compounds, overall confirm findings observed with other reported in vitro assays, and even show a significant correlation with estimated common doses. This approach, in which a large series of psychedelic NPS belonging to different subclasses is comparatively tested, using a same assay setup, monitoring a receptor-proximal event, not only gives pharmacological insights, but may also allow prioritization of legal actions related to the most potent -and potentially dangerous- compounds.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
Change history
13 August 2020
It has been brought to the authors’ attention that Fig. 1 of “In vitro structure–activity relationship determination of 30 psychedelic new psychoactive substances by means of β-arrestin 2 recruitment to the serotonin 2A receptor” contained a mistake in the structures for 2C-B-FLY and Bromo-DragonFLY. This has now been corrected. The authors apologize for any inconvenience caused.
References
Blaazer AR, Smid P, Kruse CG (2008) Structure-activity relationships of phenylalkylamines as agonist ligands for 5-HT(2A) receptors. ChemMedChem 3(9):1299–1309. https://doi.org/10.1002/cmdc.200800133
Braden MR, Parrish JC, Naylor JC, Nichols DE (2006) Molecular interaction of serotonin 5-HT2A receptor residues Phe 339(6.51) and Phe340(6.52) with superpotent N-benzyl phenethylamine agonists. Mol Pharmacol 70(6):1956–1964. https://doi.org/10.1124/mol.106.028720
Canal CE (2018) Serotonergic psychedelics: experimental approaches for assessing mechanisms of action. Handb Exp Pharmacol 252:227–260. https://doi.org/10.1007/164_2018_107
Cannaert A, Franz F, Auwarter V, Stove CP (2017) Activity-based detection of consumption of synthetic cannabinoids in authentic urine samples using a stable cannabinoid reporter system. Anal Chem 89(17):9527–9536. https://doi.org/10.1021/acs.analchem.7b02552
Cannaert A, Storme J, Franz F, Auwarter V, Stove CP (2016) Detection and activity profiling of synthetic cannabinoids and their metabolites with a newly developed bioassay. Anal Chem 88(23):11476–11485. https://doi.org/10.1021/acs.analchem.6b02600
Dean BV, Stellpflug SJ, Burnett AM, Engebretsen KM (2013) 2C or not 2C: phenethylamine designer drug review. J Med Toxicol Off J Am Coll Med Toxicol 9(2):172–178. https://doi.org/10.1007/s13181-013-0295-x
Dixon AS, Schwinn MK, Hall MP et al (2016) NanoLuc complementation reporter optimized for accurate measurement of protein interactions in cells. ACS Chem Biol 11(2):400–408. https://doi.org/10.1021/acschembio.5b00753
Elmore JS, Decker AM, Sulima A et al (2018) Comparative neuropharmacology of N-(2-methoxybenzyl)-2,5-dimethoxyphenethylamine (NBOMe) hallucinogens and their 2C counterparts in male rats. Neuropharmacology 142:240–250. https://doi.org/10.1016/j.neuropharm.2018.02.033
EMCDDA-Europol (2014) EMCDDA–Europol Joint Report on a new psychoactive substance 4-iodo-2,5-dimethoxy-N-(2-methoxybenzyl)phenethylamine (25I-NBOMe). https://www.emcdda.europa.eu/publications/joint-report/25I-NBOMe_en. Accessed Apr 2020
EMCDDA (2004) Report on the risk assessment of 2C-I, 2C-T-2 and 2C-T-7 in the framework of the joint action on new synthetic drugs. https://www.emcdda.europa.eu/publications/risk-assessments/2C-I-2C-T-2-2C-T-7_fr. Accessed Apr 2020
Eshleman AJ, Wolfrum KM, Reed JF, Kim SO, Johnson RA, Janowsky A (2018) Neurochemical pharmacology of psychoactive substituted N-benzylphenethylamines: high potency agonists at 5-HT2A receptors. Biochem Pharmacol 158:27–34. https://doi.org/10.1016/j.bcp.2018.09.024
Halberstadt AL, Chatha M, Stratford A, Grill M, Brandt SD (2019) Comparison of the behavioral responses induced by phenylalkylamine hallucinogens and their tetrahydrobenzodifuran ("FLY") and benzodifuran ("DragonFLY") analogs. Neuropharmacology 144:368–376. https://doi.org/10.1016/j.neuropharm.2018.10.037
Hansen M, Phonekeo K, Paine JS et al (2014) Synthesis and structure-activity relationships of N-benzyl phenethylamines as 5-HT2A/2C agonists. ACS Chem Neurosci 5(3):243–249. https://doi.org/10.1021/cn400216u
Hondebrink L, Zwartsen A, Westerink RHS (2018) Effect fingerprinting of new psychoactive substances (NPS): what can we learn from in vitro data? Pharmacol Ther 182:193–224. https://doi.org/10.1016/j.pharmthera.2017.10.022
Iwersen-Bergmann S, Lehmann S, Heinemann A et al (2019) Mass poisoning with NPS: 2C-E and bromo-DragonFly. Int J Legal Med 133(1):123–129. https://doi.org/10.1007/s00414-018-1882-9
Jensen AA, McCorvy JD, Leth-Petersen S et al (2017) Detailed characterization of the in vitro pharmacological and pharmacokinetic properties of n-(2-hydroxybenzyl)-2,5-dimethoxy-4-cyanophenylethylamine (25CN-NBOH), a highly selective and brain-penetrant 5-HT2A receptor agonist. J Pharmacol Exp Ther 361(3):441–453. https://doi.org/10.1124/jpet.117.239905
Kolaczynska KE, Luethi D, Trachsel D, Hoener MC, Liechti ME (2019) Receptor interaction profiles of 4-alkoxy-substituted 2,5-dimethoxyphenethylamines and related amphetamines. Front Pharmacol 10:1423. https://doi.org/10.3389/fphar.2019.01423
Kurrasch-Orbaugh DM, Watts VJ, Barker EL, Nichols DE (2003) Serotonin 5-hydroxytryptamine 2A receptor-coupled phospholipase C and phospholipase A2 signaling pathways have different receptor reserves. J Pharmacol Exp Ther 304(1):229–237. https://doi.org/10.1124/jpet.102.042184
Kyriakou C, Marinelli E, Frati P et al (2015) NBOMe: new potent hallucinogens–pharmacology, analytical methods, toxicities, fatalities: a review. Eur Rev Med Pharmaco 19(17):3270–3281
Leth-Petersen S, Petersen IN, Jensen AA et al (2016) 5-HT2A/5-HT2C receptor pharmacology and intrinsic clearance of n-benzylphenethylamines modified at the primary site of metabolism. ACS Chem Neurosci 7(11):1614–1619. https://doi.org/10.1021/acschemneuro.6b00265
Lopez-Gimenez JF, Gonzalez-Maeso J (2018) Hallucinogens and serotonin 5-HT2A receptor-mediated signaling pathways. Curr Top Behav Neurosci 36:45–73. https://doi.org/10.1007/7854_2017_478
Luethi D, Liechti ME (2018) Monoamine transporter and receptor interaction profiles in vitro predict reported human doses of novel psychoactive stimulants and psychedelics. Int J Neuropsychopharmacol 21(10):926–931. https://doi.org/10.1093/ijnp/pyy047
Luethi D, Liechti ME (2020) Designer drugs: mechanism of action and adverse effects. Arch Toxicol. https://doi.org/10.1007/s00204-020-02693-7
Luethi D, Trachsel D, Hoener MC, Liechti ME (2018) Monoamine receptor interaction profiles of 4-thio-substituted phenethylamines (2C-T drugs). Neuropharmacology 134(Pt A):141–148. https://doi.org/10.1016/j.neuropharm.2017.07.012
Luethi D, Widmer R, Trachsel D, Hoener MC, Liechti ME (2019) Monoamine receptor interaction profiles of 4-aryl-substituted 2,5-dimethoxyphenethylamines (2C-BI derivatives). Eur J Pharmacol 855:103–111. https://doi.org/10.1016/j.ejphar.2019.05.014
Moya PR, Berg KA, Gutierrez-Hernandez MA et al (2007) Functional selectivity of hallucinogenic phenethylamine and phenylisopropylamine derivatives at human 5-hydroxytryptamine (5-HT)2A and 5-HT2C receptors. J Pharmacol Exp Ther 321(3):1054–1061. https://doi.org/10.1124/jpet.106.117507
Nichols DE (2004) Hallucinogens. Pharmacol Ther 101(2):131–181. https://doi.org/10.1016/j.pharmthera.2003.11.002
Nichols DE (2016) Psychedelics. Pharmacol Rev 68(2):264–355. https://doi.org/10.1124/pr.115.011478
Nichols DE (2018) Chemistry and structure-activity relationships of psychedelics. Curr Top Behav Neurosci 36:1–43. https://doi.org/10.1007/7854_2017_475
Noble C, Holm NB, Mardal M, Linnet K (2018) Bromo-dragonfly, a psychoactive benzodifuran, is resistant to hepatic metabolism and potently inhibits monoamine oxidase A. Toxicol Lett 295:397–407. https://doi.org/10.1016/j.toxlet.2018.07.018
Parker MA, Marona-Lewicka D, Lucaites VL, Nelson DL, Nichols DE (1998) A novel (benzodifuranyl) aminoalkane with extremely potent activity at the 5-HT2A receptor. J Med Chem 41(26):5148–5149. https://doi.org/10.1021/jm9803525
Parrish JC, Braden MR, Gundy E, Nichols DE (2005) Differential phospholipase C activation by phenylalkylamine serotonin 5-HT 2A receptor agonists. J Neurochem 95(6):1575–1584. https://doi.org/10.1111/j.1471-4159.2005.03477.x
Pottie E, Cannaert A, Van Uytfanghe K, Stove CP (2019) Setup of a serotonin 2A receptor (5-HT2AR) bioassay: demonstration of its applicability to functionally characterize hallucinogenic new psychoactive substances and an explanation why 5-HT2AR bioassays are not suited for universal activity-based screening of biofluids for new psychoactive substances. Anal Chem 91(24):15444–15452. https://doi.org/10.1021/acs.analchem.9b03104
Pottie E, Tosh DK, Gao ZG, Jacobson KA, Stove CP (2020) Assessment of biased agonism at the A3 adenosine receptor using beta-arrestin and miniGalphai recruitment assays. Biochem Pharmacol 177:113934. https://doi.org/10.1016/j.bcp.2020.113934
Poulie CBM, Jensen AA, Halberstadt AL, Kristensen JL (2019) DARK classics in chemical neuroscience: NBOMes. ACS chemical neuroscience. https://doi.org/10.1021/acschemneuro.9b00528
Rickli A, Luethi D, Reinisch J, Buchy D, Hoener MC, Liechti ME (2015) Receptor interaction profiles of novel N-2-methoxybenzyl (NBOMe) derivatives of 2,5-dimethoxy-substituted phenethylamines (2C drugs). Neuropharmacology 99:546–553. https://doi.org/10.1016/j.neuropharm.2015.08.034
Rickli A, Moning OD, Hoener MC, Liechti ME (2016) Receptor interaction profiles of novel psychoactive tryptamines compared with classic hallucinogens. Eur Neuropsychopharmacol J Eur Coll Neuropsychopharmacol 26(8):1327–1337. https://doi.org/10.1016/j.euroneuro.2016.05.001
Shulgin A, Shulgin A (1991) PiHKAL: a chemical love story. Transform Press, Berkley, CA
Suzuki J, Dekker MA, Valenti ES et al (2015) Toxicities associated with NBOMe ingestion-a novel class of potent hallucinogens: a review of the literature. Psychosomatics 56(2):129–139. https://doi.org/10.1016/j.psym.2014.11.002
UNODC (2020) Current NPS threats. https://www.unodc.org/unodc/en/scientists/current-nps-threats.html. Accessed Apr 2020
Vasudevan L, Vandeputte M, Deventer M, Wouters E, Cannaert A, Stove CP (2020) Assessment of structure-activity relationships and biased agonism at the Mu opioid receptor of novel synthetic opioids using a novel, stable bio-assay platform. Biochem Pharmacol 177:113910. https://doi.org/10.1016/j.bcp.2020.113910
Wacker D, Wang S, McCorvy JD et al (2017) Crystal structure of an LSD-bound human serotonin receptor. Cell 168(3):377–389. https://doi.org/10.1016/j.cell.2016.12.033
Wouters E, Walraed J, Banister SD, Stove CP (2019) Insights into biased signaling at cannabinoid receptors: synthetic cannabinoid receptor agonists. Biochem Pharmacol 169:113623. https://doi.org/10.1016/j.bcp.2019.08.025
Wouters E, Walraed J, Robertson MJ et al (2020) Assessment of biased agonism among distinct synthetic cannabinoid receptor agonist scaffolds. ACS Pharmacol Translat Sci 3(2):285–295. https://doi.org/10.1021/acsptsci.9b00069
Acknowledgements
Alexandra Smina is acknowledged for the help during the practical implementation of the experiments. Prof. Kristof Maudens is acknowledged for kindly providing the analytical standards of 2C-B, 2C-C, 2C-I, 25B-NBOMe, 25C-NBOMe and 25I-NBOMe. The authors want to thank Chiron for the generous gift of the analytical standard of Bromo-DragonFLY. C. Stove acknowledges funding by the Research Foundation-Flanders (FWO) [G069419N] and the Ghent University–Special Research Fund (BOF) [01J15517]. A. Cannaert acknowledges funding as a postdoctoral research fellow from the Research Foundation Flanders (FWO; 12Y9520N) and the Ghent University Special Research Fund (BOF; PDO026-18).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Electronic supplementary material
Below is the link to the electronic supplementary material.
Rights and permissions
About this article
Cite this article
Pottie, E., Cannaert, A. & Stove, C.P. In vitro structure–activity relationship determination of 30 psychedelic new psychoactive substances by means of β-arrestin 2 recruitment to the serotonin 2A receptor. Arch Toxicol 94, 3449–3460 (2020). https://doi.org/10.1007/s00204-020-02836-w
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00204-020-02836-w